A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study.
Aortic stenosis
Clinical care
Health services
Prospective registry
Quality of care
TAVI
Transcatheter aortic valve implantation
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
30 Mar 2024
30 Mar 2024
Historique:
received:
18
07
2023
revised:
23
01
2024
accepted:
27
02
2024
medline:
30
3
2024
pubmed:
30
3
2024
entrez:
30
3
2024
Statut:
aheadofprint
Résumé
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries. This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety. Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%). Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries.
METHODS
METHODS
This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety.
RESULTS
RESULTS
Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%).
CONCLUSIONS
CONCLUSIONS
Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety.
Identifiants
pubmed: 38554125
pii: 7637935
doi: 10.1093/eurheartj/ehae147
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Institute for Pharmacology and Preventive Medicine GmbH
Investigateurs
Derk Frank
(D)
Gemma McCalmont
(G)
Peter Bramlage
(P)
Claudia M Lüske
(CM)
Marie Zielinski
(M)
Daniel Greinert
(D)
Cornelia Deutsch
(C)
Violetta Hachaturyan
(V)
Eric Durand
(E)
Sandra Lauck
(S)
Douglas Muir
(D)
Mark Spence
(M)
Mariuca Vasa-Nicotera
(M)
David Wood
(D)
Francesco Saia
(F)
Jana Kurucova
(J)
Wilbert Wesselink
(W)
Radka Rakova
(R)
Martin Thoenes
(M)
Cristóbal A Urbano-Carrillo
(CA)
Carlos Lara García
(CL)
Beatriz Chamorro
(B)
Damien Bouchayer
(D)
Jean-Philippe Claudel
(JP)
Hervé Perrier
(H)
Viktoria Frebault
(V)
Vlad Anton Iliescu
(VA)
Catalina Andreea Parasca
(CA)
Christophe Saint Etienne
(CS)
Katia Lassouani
(K)
Florence Leclercq
(F)
Wassim Zitouni
(W)
Sonia Soltani
(S)
Vincent Auffret
(V)
Rosalie Le Gal
(RL)
Lluis Asmarats
(L)
Elena Jimenez Xarrie
(EJ)
Carlo Di Mario
(C)
Niccolo Ciardetti
(N)
Francesco Meucci
(F)
Aurelie Veugeois
(A)
Imane Bagdadi
(I)
Jiri Maly
(J)
Lenka Kolinova
(L)
Andreas Schober
(A)
Georg Delle-Karth
(G)
Claudia Schuster
(C)
Marie-Christine Leitgeb
(MC)
Luis Nombela-Franco
(L)
Esther Bernardo García
(EB)
María Aránzazu Ortega Pozzi
(MAO)
Nikos Werner
(N)
Jürgen Leick
(J)
Michael Lauterbach
(M)
Hannah Waschbüsch
(H)
Joan Antoni
(J)
Guillem Muntané
(G)
Julia Mascherbauer Olga Daxböck
(JMO)
Mirela Butkovic
(M)
Simona Popescu
(S)
Giuseppe Musumeci
(G)
Martina Perrero
(M)
Nicolas Meneveau
(N)
Stephanie Watbled
(S)
Thibaud Meurice
(T)
Maxence Delomez
(M)
Felix Mahfoud
(F)
Bruno Scheller
(B)
Sebastian Ewen
(S)
Ann-Kathrin Berger
(AK)
Christina Koch
(C)
Alexandra Engel
(A)
Federico De Marco
(F)
Paolo Olivares
(P)
Tim Seidler
(T)
Frieder Wolf
(F)
Carolin Müller
(C)
Maren Hünermund
(M)
Florian Leuschner
(F)
Mathias Konstandin
(M)
Lisa Linz
(L)
Hannah Ulbricht
(H)
Patrick Joly
(P)
Sabrina Siame
(S)
Jean-Philippe Collet
(JP)
Nassima Ait Amrane
(NA)
Ferdinand Vogt
(F)
Dow Rosenzweig
(D)
Emilio Di Lorenzo
(E)
Barbara Cefalo
(B)
Elmar Kuhn
(E)
Vera Wolf
(V)
Vicente Peral Disdier
(VP)
Jaume Maristany Daunert
(JM)
Maria Carmen de la Bandera Sanchez
(MC)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.